EUA Selected to Design Arrowhead Research Corporation's Madi
Mar 9, 2016 18:07:58 GMT -5
Think2Succeed and qbeing1010 like this
Post by partimefriend on Mar 9, 2016 18:07:58 GMT -5
Eppstein Uhen Architects (EUA) was selected by Arrowhead Research Corporation (ARC) to design the company’s new Madison, Wisconsin facility as part of University Research Park. The 45,000 square-foot facility will include biology and chemistry laboratories and other specialty laboratory spaces to support the expansion of research and development at the company. Eppstein Uhen Architects will lead the design process and guide the project on a tight schedule to plan and coordinate completion by August 2016.
As a leader within the Science and Technology market, EUA is honored and excited to partner with ARC to design a world-class facility to serve the company for many years. EUA has elaborate and wide-ranging S+T experience with over 1,000,000-square-feet of unique laboratory space designed to meet the needs of large technology corporations and higher education facilities.
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate™ delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus, ARC-AAT for liver disease associated with alpha- 1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic diseases, and ARC-HIF2 for renal cell carcinoma.
Eppstein Uhen Architects (EUA) is best known for designing environments that elevate people’s potential. More than 150 employees in Milwaukee, Madison and Des Moines demonstrate unparalleled commitment to the markets, communities and clients they serve. The respected 108-year old firm specializes in several markets including workplace, healthcare, education, senior living, student housing and mixed-use. For additional information, please visit the firm’s website at eua.com.
Arrowhead Research expanding its lab space in Madison
Arrowhead Research Corp., a California company that is aiming to develop a cure for hepatitis B, is planning to expand its research facilities in Madison with construction of a 45,000 square-foot laboratory facility.
"This expansion shows confidence in their method of treatment, R&D investment, and in Wisconsin as an ecosystem of research," said Brian Moeller, operations manager at BioForward, the trade association for the state's biotech industry.
The building, which Arrowhead hopes to complete by August, will be designed by Eppstein Uhen Architects, the firm said in a news release. It will be in University Research Park on Madison's west side.
Pasadena-Calif.-based Arrowhead, whose shares trade on the Nasdaq market, said in November that a drug it has in clinical trials could produce "deep and durable reductions" of hepatitis B antigens and DNA. A study with humans and another with chimps showed that the drug had substantial effects in treating the chronic liver infection.
As a leader within the Science and Technology market, EUA is honored and excited to partner with ARC to design a world-class facility to serve the company for many years. EUA has elaborate and wide-ranging S+T experience with over 1,000,000-square-feet of unique laboratory space designed to meet the needs of large technology corporations and higher education facilities.
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate™ delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus, ARC-AAT for liver disease associated with alpha- 1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic diseases, and ARC-HIF2 for renal cell carcinoma.
Eppstein Uhen Architects (EUA) is best known for designing environments that elevate people’s potential. More than 150 employees in Milwaukee, Madison and Des Moines demonstrate unparalleled commitment to the markets, communities and clients they serve. The respected 108-year old firm specializes in several markets including workplace, healthcare, education, senior living, student housing and mixed-use. For additional information, please visit the firm’s website at eua.com.
Arrowhead Research expanding its lab space in Madison
Arrowhead Research Corp., a California company that is aiming to develop a cure for hepatitis B, is planning to expand its research facilities in Madison with construction of a 45,000 square-foot laboratory facility.
"This expansion shows confidence in their method of treatment, R&D investment, and in Wisconsin as an ecosystem of research," said Brian Moeller, operations manager at BioForward, the trade association for the state's biotech industry.
The building, which Arrowhead hopes to complete by August, will be designed by Eppstein Uhen Architects, the firm said in a news release. It will be in University Research Park on Madison's west side.
Pasadena-Calif.-based Arrowhead, whose shares trade on the Nasdaq market, said in November that a drug it has in clinical trials could produce "deep and durable reductions" of hepatitis B antigens and DNA. A study with humans and another with chimps showed that the drug had substantial effects in treating the chronic liver infection.
